Acneiform eruption induced by epidermal growth factor receptor inhibitors in patients with solid tumours

被引：132

作者：

Jacot, W

Bessis, D

Jorda, E

Ychou, M

Fabbro, M

Pujol, JL

Guillot, B

机构：

[1] CHU Montpellier, Hop St Eloi, Dept Dermatol, F-34295 Montpellier 5, France

[2] Montpellier Acad Hosp, Dept Thorac Oncol, Montpellier, France

[3] Hosp Clin Univ, Dept Dermatol, Valencia, Spain

[4] CRLC Montpellier, Dept Med Oncol, Montpellier, France

来源：

BRITISH JOURNAL OF DERMATOLOGY | 2004年 / 151卷 / 01期

关键词：

D O I：

10.1111/j.1365-2133.2004.06026.x

中图分类号：

R75 [皮肤病学与性病学];

学科分类号：

100206 ;

摘要：

引用

页码：238 / 241

页数：4

共 10 条

[1] Phase I safety, pharmacokinetic, and pharmacodynamic trial of ZD1839, a selective oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with five selected solid tumor types [J].

Baselga, J ;

Rischin, D ;

Ranson, M ;

Calvert, H ;

Raymond, E ;

Kieback, DG ;

Kaye, SB ;

Gianni, L ;

Harris, A ;

Bjork, T ;

Averbuch, SD ;

Feyereislova, A ;

Swaisland, H ;

Rojo, F ;

Albanell, J .

JOURNAL OF CLINICAL ONCOLOGY, 2002, 20 (21) :4292-4302

[2] Cutaneous side-effects in cancer patients treated with the antiepidermal growth factor receptor antibody C225 [J].

Busam, KJ ;

Capodieci, P ;

Motzer, R ;

Kiehn, T ;

Phelan, D ;

Halpern, AC .

BRITISH JOURNAL OF DERMATOLOGY, 2001, 144 (06) :1169-1176

[3] Phase II trial of ZD1839 in recurrent or metastatic squamous cell carcinoma of the head and neck [J].

Cohen, EEW ;

Rosen, F ;

Stadler, WM ;

Recant, W ;

Stenson, K ;

Huo, DZ ;

Vokes, EE .

JOURNAL OF CLINICAL ONCOLOGY, 2003, 21 (10) :1980-1987

[4] Gefitinib [J].

Culy, CR ;

Faulds, D .

DRUGS, 2002, 62 (15) :2237-2248

[5] Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer [J].

Fukuoka, M ;

Yano, S ;

Giaccone, G ;

Tamura, T ;

Nakagawa, K ;

Douillard, JY ;

Nishiwaki, Y ;

Vansteenkiste, J ;

Kudoh, S ;

Rischin, D ;

Eek, R ;

Horai, T ;

Noda, K ;

Takata, I ;

Smit, E ;

Averbuch, S ;

Macleod, A ;

Feyereislova, A ;

Dong, RP ;

Baselga, J .

JOURNAL OF CLINICAL ONCOLOGY, 2003, 21 (12) :2237-2246

[6] Targeting the epidermal growth factor receptor for cancer therapy [J].

Mendelsohn, J .

JOURNAL OF CLINICAL ONCOLOGY, 2002, 20 (18) :1S-13S

[7] Phase II trial of antiepidermal growth factor receptor antibody C225 in patients with advanced renal cell carcinoma [J].

Motzer, RJ ;

Amato, R ;

Todd, M ;

Hwu, WJP ;

Cohen, R ;

Baselga, J ;

Muss, H ;

Cooper, M ;

Yu, R ;

Ginsberg, MS ;

Needle, M .

INVESTIGATIONAL NEW DRUGS, 2003, 21 (01) :99-101

[8] Phase I pharmacokinetic trial of the selective oral epidermal growth factor receptor tyrosine kinase inhibitor gefitinib ('Iressa', ZD1839) in Japanese patients with solid malignant tumors [J].

Nakagawa, K ;

Tamura, T ;

Negoro, S ;

Kudoh, S ;

Yamamoto, N ;

Takeda, K ;

Swaisland, H ;

Nakatani, I ;

Hirose, M ;

Dong, RP ;

Fukuoka, M .

ANNALS OF ONCOLOGY, 2003, 14 (06) :922-930

[9] Acneiform dermatoses [J].

Plewig, G ;

Jansen, T .

DERMATOLOGY, 1998, 196 (01) :102-107

[10] Follicular and epidermal alterations in patients treated with ZD1839 (Iressa), an inhibitor of the epidermal growth factor receptor [J].

van Doorn, R ;

Kirtschig, G ;

Scheffer, E ;

Stoof, TJ ;

Giaccone, G .

BRITISH JOURNAL OF DERMATOLOGY, 2002, 147 (03) :598-601

← 1 →